MT-1303

Published

dm+d

Unassigned

New Medicines

Multiple sclerosis (MS)

Information

New molecular entity
Biogen
Biogen

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Oct 16: Biogen discontinues development of MT-1303 after reviewing their priorities [1].

Category

An immunosupressant, selective sphingosine-1-phosphate1 (S1P1) receptor modulator [2]
In England and Wales the annual incidence and prevalence of MS is 3.5-6.6 and 100-120 per 100,000, respectively.
Multiple sclerosis (MS)
Oral